- Home
- ENTA vs BIOA Comparison
ENTA vs BIOA Comparison
Compare ENTA & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- BIOA
- Stock Information
- Founded
- ENTA 1995
- BIOA 2015
- Country
- ENTA United States
- BIOA United States
- Employees
- ENTA N/A
- BIOA N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- BIOA Biotechnology: Pharmaceutical Preparations
- Sector
- ENTA Health Care
- BIOA Health Care
- Exchange
- ENTA Nasdaq
- BIOA Nasdaq
- Market Cap
- ENTA 160.3M
- BIOA 153.4M
- IPO Year
- ENTA 2013
- BIOA 2024
- Fundamental
- Price
- ENTA $7.89
- BIOA $4.28
- Analyst Decision
- ENTA Buy
- BIOA Hold
- Analyst Count
- ENTA 4
- BIOA 4
- Target Price
- ENTA $18.00
- BIOA $5.67
- AVG Volume (30 Days)
- ENTA 181.3K
- BIOA 338.3K
- Earning Date
- ENTA 08-04-2025
- BIOA 08-15-2025
- Dividend Yield
- ENTA N/A
- BIOA N/A
- EPS Growth
- ENTA N/A
- BIOA N/A
- EPS
- ENTA N/A
- BIOA N/A
- Revenue
- ENTA $64,462,999.00
- BIOA $1,451,000.00
- Revenue This Year
- ENTA N/A
- BIOA N/A
- Revenue Next Year
- ENTA $0.48
- BIOA N/A
- P/E Ratio
- ENTA N/A
- BIOA N/A
- Revenue Growth
- ENTA N/A
- BIOA N/A
- 52 Week Low
- ENTA $4.09
- BIOA $2.88
- 52 Week High
- ENTA $17.24
- BIOA $26.62
- Technical
- Relative Strength Index (RSI)
- ENTA 67.33
- BIOA N/A
- Support Level
- ENTA $6.95
- BIOA N/A
- Resistance Level
- ENTA $8.23
- BIOA N/A
- Average True Range (ATR)
- ENTA 0.40
- BIOA 0.00
- MACD
- ENTA 0.00
- BIOA 0.00
- Stochastic Oscillator
- ENTA 75.11
- BIOA 0.00
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.